Labiotech.eu - Europe's leading Biotech News Website

Latest Posts

dupixent sanofi regeneron europe

News and Trends 2 Oct 2017

Update: The EU Approval of Dupixent Might Bring its Pricing Polemic to Europe

Update (01/10/2017): The European Commission has tighter control over pricing that governments have over here Images via Tero Vesalainen, Roman Stetsyk /Shutterstock

October 2, 2017 - 1 minutemin - By Clara Rodríguez Fernández

Darya Warner life textures

News and Trends 30 Sep 2017

The Art of Darya Warner: Bacterial Portraits, Meaty Tomatoes and Bioluminescence

From beautiful microscopic stills to designing the technology of the future, artist Darya Warner captures the beauty of life in her work. Darya Warner is an artist originally from Belarus, now based in the US, with an eye to spot beauty under the light of the microscope. From genetically engineered fluorescent E. coli to cauliflower, […]

September 30, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

human bone screw surgery 1

News and Trends 29 Sep 2017

Austrian Scientists Turn Human Bone into Surgical Screws

An alternative approach for the repair of broken bones is being developed in Austria, which would overcome major limitations of metal surgical screws. Researchers from TU Graz, Austria, are working with the start-up surgebright to develop surgical screws from donated human bone for foot and jaw surgery. Metal screws are the current standard but these have major limitations […]

September 29, 2017 - 3 minutesmins - By Alex Dale

lnc therapeutics microbiome series c

News and Trends 28 Sep 2017

French Microbiome Biotech Gets a €6.5M Leg Up to Market Launch

LNC Therapeutics is ready to take its oral microbiome-based therapeutic to market for obesity. Investors have contributed a bit of cash to get it there. Bordeaux-based LNC Therapeutics has raked in €6.5M in a Series C. It has raised a total of €16.5M since it was founded in 2010. Seventure Partners, a leading VC focused […]

September 28, 2017 - 2 minutesmins - By Evelyn Warner

solid cancers immatics trial

News and Trends 28 Sep 2017

German Pharma Enters the Clinic with Solid Tumor Treatment

A Phase I study will investigate the safety and tolerability of Immatics approach to treating solid tumors. Immatics is a German biopharma based in Tuebingen, which is a leader in the field of cancer immunotherapy. It has announced today the initiation of a Phase I trial that will test the safety and tolerability of its […]

September 28, 2017 - 2 minutesmins - By Alex Dale

Mark Vaeck antibodies 1

Interview 28 Sep 2017

What are Alphabodies and How Do They Drug the Undruggable?

Philip found out more about a new form of protein therapeutics being developed by Complix, which aims to drug the undruggable. Mark Vaeck, Co-Founder and CEO of Complix, has over 25 years experience in the biotech and pharma industries. His latest company Complix, a Belgian immuno-oncology biotech, is developing Alphabodies, tiny therapeutic proteins that can […]

September 28, 2017 - 3 minutesmins - By Alex Dale

ADVERTISEMENT

exscientia evotec ai investment 1

News and Trends 28 Sep 2017

Everyone Wants a Piece of this Scottish Biotech’s AI

Evotec has doubled down on its investment in Exscientia: the German outfit just announced it has invested €15M to take a minority stake. Sanofi, GSK and Evotec have all jumped at the opportunity to work with Exscientia, a Scottish startup founded in 2012 and incubating in Dundee. Now, Evotec has gone beyond the initial immuno-oncology deal […]

September 28, 2017 - 1 minutemin - By Evelyn Warner

nightstar gene therapy ipo

News and Trends 28 Sep 2017

Oxford Spinout goes for $75M IPO on Nasdaq to Fund Gene Therapy Programs

Nightstar has gone public on the American market with the aim of raising $75M for its gene-based retinal disease cures. Spun out from Oxford in 2013, Nightstar is developing and commercializing one-shot gene therapies for various eye diseases that could lead to blindness. This morning, it debuted on the Nasdaq with a projected $75M (£56M / €64M) […]

September 28, 2017 - 2 minutesmins - By Evelyn Warner

hiv study results abivax 1

News and Trends 28 Sep 2017

Study Results Confirm that Abivax’s Treatment Towards an HIV Cure Gets Rid of Virus

Abivax’s HIV cure candidate, ABX464, caused a significant drop in the viral reservoir over an extended period during a Phase IIa study. Abivax targets the immune system to cure viral diseases. The company has announced initial results from the first cohort of patients in its most recent Phase IIa trial testing its potential HIV cure, ABX464. Initial […]

September 28, 2017 - 2 minutesmins - By Alex Dale

why labiotech exist table football

Inside Labiotech 28 Sep 2017

Why does Labiotech.eu exist? (Not only to play table football together)

Our mission, since we started Labiotech.eu, has been to empower biotech ecosystems to better cure, feed and fuel the world. In our team, we all believe biotech is an industry that has an enormous impact on making the world a better place (I can’t actually think of any more impactful industry). Bill Gates recently told […]

September 28, 2017 - 3 minutesmins - By Philip Hemme

david pardoe lifearc interview

Interview 28 Sep 2017

Ethical Drug Development can Start with Charity Investors: A Conversation

As the furor over drug pricing has driven the biopharma industry to reflect on its ethics, I sat down with David Pardoe of LifeArc to discuss the involvement of charity investors. In August, a story emerged that Novartis CEO Joe Jimenez not only responded to a patient’s letter but met with him soon thereafter to […]

September 28, 2017 - 6 minutesmins - By Evelyn Warner

markus biotech vc

Interview 27 Sep 2017

What’s this Top Swiss VC Up To These Days? General Partner Tells All

Philip caught up with Markus Hosang to find out which companies the VC is keeping an eye on after its next round of fundraising. General Partner, Markus Hosang has a strong background in pharma and VC, which serves him well when searching through the bustling biotech industry in Europe. BioMed Partners is a very active […]

September 27, 2017 - 3 minutesmins - By Alex Dale

ADVERTISEMENT